Summary & Overview
HCPCS Q3001: Radioelements for Brachytherapy, Each
HCPCS Level II code Q3001 denotes individual radioelements for brachytherapy, used to deliver localized internal radiation therapy for malignant and select benign conditions. The code captures the supply of each radioactive source used in brachytherapy implants or interstitial procedures and is important for accurate facility and supply billing in radiation oncology. Nationally, appropriate coding of brachytherapy supplies affects reimbursement flows for hospitals, outpatient departments, and ambulatory surgical centers and supports tracking of utilization for oncology services.
Key payers in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise description of clinical context and service settings, plus what to expect in payer coverage and billing practice discussions: benchmark considerations for supply-level coding, common modifier usage (listed separately), and coding relationships relevant to brachytherapy delivery. The publication highlights policy and coverage considerations at a national level, clarifies the service type and typical sites of service, and identifies areas where additional documentation or payer-specific rules frequently apply.
Data not available in the input is noted where payer-specific rates, ICD-10 pairings, and taxonomy details are required for deeper benchmarking or claims-level guidance.
Billing Code Overview
HCPCS Level II code Q3001 represents radioelements for brachytherapy, any type, each. This itemized supply is used when radioactive sources are provided for brachytherapy procedures, which deliver targeted radiation by placing radioelements directly into or near tumor tissue.
Service Type: Brachytherapy supply / radioactive implant
Typical Site of Service: Radiation oncology clinic, hospital outpatient department, ambulatory surgical center
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is a 65-year-old with localized prostate adenocarcinoma previously staged with imaging and biopsy who is scheduled for low-dose-rate (LDR) or high-dose-rate (HDR) brachytherapy. The clinical workflow begins with pre-procedure planning: consultation with radiation oncology, review of prior imaging, and treatment planning CT or ultrasound to map target volumes and organs at risk. On the day of the procedure the patient is brought to the procedure suite or operating room; conscious sedation or general anesthesia is administered as appropriate. The brachytherapy team (radiation oncologist, medical physicist, and brachytherapy nurse or technologist) prepares Q3001 radioelements for implantation. For LDR, sealed radioactive seeds are placed transperineally under ultrasound guidance into the prostate; for HDR, temporary catheters are placed and the radioelements (sources) are loaded for prescribed dwell times. Post-implant dosimetry or treatment verification imaging is performed before discharge. Typical site of service is an ambulatory surgical center or hospital operating/procedure room with specialized radiation safety controls. Typical patient scenario also includes breast, gynecologic, or ocular malignancies when brachytherapy radioelements specified by Q3001 are used for localized therapy.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 |